- Johnson & Johnson said on Friday its cancer drug, Carvykti, met the main goal of a late-stage study for treating patients with a type of myeloma, according to an interim analysis.
(Reporting by Raghav Mahobe in Bengaluru; Editing by Vinay Dwivedi)
J&J's Carvykti succeeds in late-stage trial for a type of blood cancer
Regulated by IMPRESS:
The Independent Monitor
for the Press CIC
IMPRESS, 16-18 New Bridge Street,
London, EC4V 6AG
T: 020 3325 4288
E: complaints@impress.press
W: impress.press